420 related articles for article (PubMed ID: 23550846)
21. Single 6-mg dose of rasburicase: The experience in a large academic medical center.
Nauffal M; Redd R; Ni J; Stone RM; DeAngelo DJ; McDonnell AM
J Oncol Pharm Pract; 2019 Sep; 25(6):1349-1356. PubMed ID: 30111244
[TBL] [Abstract][Full Text] [Related]
22. A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis.
Goldman SC; Holcenberg JS; Finklestein JZ; Hutchinson R; Kreissman S; Johnson FL; Tou C; Harvey E; Morris E; Cairo MS
Blood; 2001 May; 97(10):2998-3003. PubMed ID: 11342423
[TBL] [Abstract][Full Text] [Related]
23. A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome.
Vadhan-Raj S; Fayad LE; Fanale MA; Pro B; Rodriguez A; Hagemeister FB; Bueso-Ramos CE; Zhou X; McLaughlin PW; Fowler N; Shah J; Orlowski RZ; Samaniego F; Wang M; Cortes JE; Younes A; Kwak LW; Sarlis NJ; Romaguera JE
Ann Oncol; 2012 Jun; 23(6):1640-5. PubMed ID: 22015451
[TBL] [Abstract][Full Text] [Related]
24. Rasburicase: a new approach for preventing and/or treating tumor lysis syndrome.
Bessmertny O; Robitaille LM; Cairo MS
Curr Pharm Des; 2005; 11(32):4177-85. PubMed ID: 16375739
[TBL] [Abstract][Full Text] [Related]
25. Economic comparison of rasburicase and allopurinol for treatment of tumor lysis syndrome in pediatric patients.
Eaddy M; Seal B; Tangirala M; Davies EH; O'Day K
Am J Health Syst Pharm; 2010 Dec; 67(24):2110-4. PubMed ID: 21116002
[TBL] [Abstract][Full Text] [Related]
26. Single 4.5 mg fixed-dose of rasburicase for hyperuricemia associated with tumor lysis syndrome.
Patel KS; Lau JE; Zembillas AS; Gallagher EM
J Oncol Pharm Pract; 2017 Jul; 23(5):333-337. PubMed ID: 27084514
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of Single Low-Dose Rasburicase in Management of Tumor Lysis Syndrome in Leukemia and Lymphoma Patients.
Gupta G; Seth T; Garg V; Juneja R; Mahapatra M; Datta SK; Upadhyay AD; Saxena R
Clin Lymphoma Myeloma Leuk; 2021 Jan; 21(1):e99-e104. PubMed ID: 33039358
[TBL] [Abstract][Full Text] [Related]
28. Rasburicase for the prevention and treatment of hyperuricemia in tumor lysis syndrome.
Kennedy LD; Ajiboye VO
J Oncol Pharm Pract; 2010 Sep; 16(3):205-13. PubMed ID: 19923162
[TBL] [Abstract][Full Text] [Related]
29. Effective treatment and prophylaxis of hyperuricemia and impaired renal function in tumor lysis syndrome with low doses of rasburicase.
Hummel M; Reiter S; Adam K; Hehlmann R; Buchheidt D
Eur J Haematol; 2008 Apr; 80(4):331-6. PubMed ID: 18081720
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAAL1 (Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma) study.
Coiffier B; Mounier N; Bologna S; Fermé C; Tilly H; Sonet A; Christian B; Casasnovas O; Jourdan E; Belhadj K; Herbrecht R;
J Clin Oncol; 2003 Dec; 21(23):4402-6. PubMed ID: 14581437
[TBL] [Abstract][Full Text] [Related]
31. Effectiveness of Single-dose Rasburicase in Patients With Lymphoid Malignancies at a High Risk for Tumor Lysis Syndrome.
Jeon YW; Kwak DH; Park SS; Yoon JH; Lee SE; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Lee JW; Min WS; Cho SG
Clin Lymphoma Myeloma Leuk; 2017 Sep; 17(9):595-603. PubMed ID: 28711571
[TBL] [Abstract][Full Text] [Related]
32. A phase 2 trial of single low doses of rasburicase for treatment of hyperuricemia in adult patients with acute leukemia.
Vachhani P; Baron J; Freyer CW; Miller A; Wetzler M; Thompson JE; Griffiths EA; Wang ES
Leuk Res; 2021 Aug; 107():106588. PubMed ID: 33957371
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of rasburicase (recombinant urate oxidase) in the prevention and treatment of malignancy-associated hyperuricemia: an Indian experience.
Digumarti R; Sinha S; Nirni SS; Patil SG; Pedapenki RM
Indian J Cancer; 2014; 51(2):180-3. PubMed ID: 25104205
[TBL] [Abstract][Full Text] [Related]
34. The value of fixed rasburicase dosing versus weight-based dosing in the treatment and prevention of tumor lysis syndrome.
Boutin A; Blackman A; O'Sullivan DM; Forcello N
J Oncol Pharm Pract; 2019 Apr; 25(3):577-583. PubMed ID: 29320954
[TBL] [Abstract][Full Text] [Related]
35. Rational use of rasburicase for the treatment and management of tumor lysis syndrome.
Shaikh SA; Marini BL; Hough SM; Perissinotti AJ
J Oncol Pharm Pract; 2018 Apr; 24(3):176-184. PubMed ID: 28077046
[TBL] [Abstract][Full Text] [Related]
36. Rasburicase in cancer-related hyperuricemia.
Rodriguez M; Campara M; Haaf C
Drugs Today (Barc); 2011 Aug; 47(8):591-603. PubMed ID: 21850282
[TBL] [Abstract][Full Text] [Related]
37. Reduced-dose rasburicase (recombinant xanthine oxidase) in adult cancer patients with hyperuricemia.
Trifilio S; Gordon L; Singhal S; Tallman M; Evens A; Rashid K; Fishman M; Masino K; Pi J; Mehta J
Bone Marrow Transplant; 2006 Jun; 37(11):997-1001. PubMed ID: 16708061
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness analysis of rasburicase over standard of care for the prevention and treatment of tumor lysis syndrome in children with hematologic malignancies in China.
Hu S; Han Y; Zhang W; Zhang T; Yao X; Liu L
J Med Econ; 2019 Aug; 22(8):742-750. PubMed ID: 30939962
[No Abstract] [Full Text] [Related]
39. Elitek-rasburicase: an effective means to prevent and treat hyperuricemia associated with tumor lysis syndrome, a Meeting Report, Dallas, Texas, January 2002.
Navolanic PM; Pui CH; Larson RA; Bishop MR; Pearce TE; Cairo MS; Goldman SC; Jeha SC; Shanholtz CB; Leonard JP; McCubrey JA
Leukemia; 2003 Mar; 17(3):499-514. PubMed ID: 12646938
[TBL] [Abstract][Full Text] [Related]
40. A retrospective analysis of tumor lysis syndrome management in a quaternary care hospital.
Eng S; Lee CS; Ahn S; Sharma A
J Oncol Pharm Pract; 2020 Mar; 26(2):338-344. PubMed ID: 31088218
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
